A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C; Liver cirrhosis
- Focus Therapeutic Use
- Sponsors AbbVie
- 22 Jun 2018 Planned number of patients changed from 270 to 330.
- 22 Jun 2018 Planned End Date changed from 10 Dec 2018 to 2 Nov 2019.
- 22 Jun 2018 Planned primary completion date changed from 24 May 2018 to 18 May 2019.